INNOVIVA, INC. Prepaid Expense and Other Assets, Current
INNOVIVA, INC. (INVA) had Prepaid Expense and Other Assets, Current of $24.41 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Prepaid Expense and Other Assets, Current $24.41M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $24.84M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $26.72M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $19.41M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $24.41M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $24.84M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $26.72M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $19.41M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $16.61M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $15.41M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $21.06M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $12.65M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $8.48M 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $16.55M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $21.63M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $14.73M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $20.54M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $24.12M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $29.56M 10-K/A · filed 2024-03-05 | |
| 2022-09-30 | $7.93M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $3.95M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $5.58M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $1.37M 10-K · filed 2023-02-28 | $1.44M 10-K · filed 2022-02-28 |
| 2021-09-30 | $542.00K 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $734.00K 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $1.07M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $1.64M 10-K/A · filed 2022-03-17 | |
| 2020-09-30 | $698.00K 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $645.00K 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $822.00K 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $962.00K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $383.00K 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $459.00K 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $702.00K 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $849.00K 10-K · filed 2020-02-19 | |
| 2018-09-30 | $513.00K 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $576.00K 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $950.00K 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $754.00K 10-K · filed 2019-02-19 | |
| 2017-09-30 | $439.00K 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $642.00K 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $880.00K 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $766.00K 10-K · filed 2018-02-23 | |
| 2016-09-30 | $534.00K 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $738.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $975.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $814.00K 10-K · filed 2017-02-28 | |
| 2015-09-30 | $615.00K 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $697.00K 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $1.01M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $1.13M 10-K · filed 2016-02-24 | |
| 2014-09-30 | $748.00K 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $982.00K 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $6.39M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $4.29M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $4.07M 10-Q · filed 2013-11-01 | |
| 2013-06-30 | $3.61M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $5.19M 10-Q · filed 2013-05-01 | |
| 2012-12-31 | $4.07M 10-K · filed 2014-03-03 | $3.97M 10-K · filed 2013-02-26 |
| 2012-09-30 | $3.77M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $3.40M 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $3.90M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $3.52M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $3.85M 10-Q · filed 2011-11-02 | |
| 2011-06-30 | $4.51M 10-Q · filed 2011-08-03 | |
| 2010-12-31 | $6.00M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |